PIONEER: Psychiatric and Immune phenotyping of rare genetic neurodevelopmental syndromes
- Conditions
- 10027665Neurodevelopmental disorders1008362410037173
- Registration Number
- NL-OMON56785
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 120
To be eligible to participate in this study, a subject must meet all the
following criteria:
• Molecular confirmed syndrome diagnosis (confirmed pathogenic defect in DDX3X,
SETD1A, KANSL1, ANKRD11, DYRK1A, PPM1D, YY1, RAI1, or a 17p11.2 deletion)
• Age 4 years and above
• The participant and/or their carers are fluent in Dutch
• Written informed consent
For controls we have the following inclusion criteria:
• No indications for the presence of a RGNS
• Age above 10 years
• The participant and/or their carers are fluent in Dutch
• Written informed consent by participant, legal guardian, or both if
applicable.
There are no exclusioncriteria for the participants.
For controls we have the following exclusion criteria:
• A known diagnosis of a systemic (auto)immune disorder (e.g. any disease
affecting the immune cells, systematic lupus erythematosus and related
disorders, rheumatoid artritis, vasculitis, systemic sclerodermia)
• Use of an immunosuppressive agent (e.g. corticosteroids, azathioprin,
ciclosporin, hydroxychloroquin, methotrexate, tacrolimus, biologicals)
• Fever or clinical signs of infection at the moment of venipuncture
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Per participant:<br /><br>1. Immunological profile (based on medical history, blood measures)<br /><br>2. Outcomes of neurocognitive and behavioral measures: outcomes of the<br /><br>different questionnaires and intelligence tests. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Not applicable. </p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.